References
- Guray M, Sahin AA. Benign breast diseases: classification, diagnosis, and management. Oncologist 2006; 11: 435-49. 10.1634/theoncologist.11-5-435
- Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146-51. 10.1056/NEJM198501173120303
- Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, etal. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993; 71: 1258-65.
- Ellis IO. Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology. Modern Pathology 2010; 23(Suppl 2): S1-7.10.1038/modpathol.2010.56
- ƠFlynn EAM. Diagnosis of primary breast cancer. In: Luna A, Vilanova JC, Celso Hygino Da Cruz Jr. LC, Rossi SE, editors. Functional imaging in oncology: clinical applications. Berlin Heidelberg: Springer-Verlag; 2014. p. 816-37.
- D'Orsi CJ, Sickles EA, Mendelson EB, Morris EA. ACR BI-RADS atlas, breast imaging reporting and data system. Reston, VA: American College ofRadiology; 2013.
- Millet I, Pages E, Hoa D, Merigeaud S, Curros Doyon F, Prat X, et al. Pearls and pitfalls in breast MRI. Br J Radiol 2012; 85: 197-207. 10.1259/bjr/47213729
- Thomassin-Naggara I, Salem C, Darai E, Bazot M, Uzan S, Marsault C, et al. Non-mass like enhancement on breast MRI: interpretation pearls. JRadiol2009; 90: 269-75. doi: JR-04-2009-90-4-0221-0363-101019-200904045
- Yabuuchi H, Matsuo Y, Kamitani T, Setoguchi, Okafuji T, Soeda H, et al. Non-mass-like enhancement on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. Eur J Radiol 2010; 75: 126-32. doi:10.1016/j.ejrad.2009.09.013
- Nadrljanski M, Markovic BB, Milosevic ZC. Breast ductal carcinoma in situ(DCIS): morphologic and kinetic MRI findings. Iran J Radiol 2013; 10: 99-102.10.5812/iranjradiol.4876
- Nadrljanski M, Miloš evic ZČ, Plešinac-Karapandžić V, Goldner B. Značaj magnetne rezonancije dojki u dijagnostici duktalnog karcinoma in situ. Srp ArhCelok Lek 2013; 141: 402-8. 10.2298/SARH1306402N
- Japan Association of Breast and Thyroid Sonology. Guideline for breast ultrasound: management and diagnosis. Tokyo: Nankodo Co.; 2004. p. 35-7.
- Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, et al. Magnetic resonance imaging of the breast: Recommendations from theEUSOMA working group. Eur J Cancer 2010; 46: 1296-316. 10.1016/j.ejca.2010.02.015
- Nadrljanski MM, Miloševic ZC, Pleš inac-Karapandžic V, Maksimovic R. MRIin the evaluation of breast cancer patient response to neoadjuvant chemotherapy: predictive factors for breast conservative surgery. Diagn Interv Radiol 2013; 19: 463-70. 10.5152/dir.2013.13201
- Povoski SP, Neff RL, Mojzisik CM, O’Malley DM, Hinkle GH, Hall NC, et al. A comprehensive overview of radioguided surgery using gamma detectionprobe technology. World J Surg Oncol 2009; 7: 7-11. 10.1186/1477-7819-7-11
- Santen RJ, Mansel R. Benign Breast Disorders. N Engl J Med 2005; 353: 275-85. 10.1056/NEJMra035692
- Goehring C, Morabia A. Epidemiology of benign breast disease, with specialattention to histologic types. Epidemiol Rev 1997; 19: 310-27.
- Wu C, Ray RM, Lin MG, Gao DL, Horner NK, Nelson ZC, et al. A case-control study of risk factors for fibrocystic breast conditions. Am J Epidemiol 2004;160: 945-60. 10.1093/aje/kwh318
- Chen JH, Liu H, Baek HM, Nalcioglu O, Su MY. MR imaging features of fibrocystic change of the breast. Magn Reson Imaging 2008; 26: 1207-14. doi:10.1016/j.mri.2008.02.004
- Chen JH, Nalcioglu O, Su MY. Fibrocystic change of the breast presenting as afocal lesion mimicking breast cancer in MR imaging. J Magn Reson Imaging 2008; 28: 1499-505. 10.1002/jmri.21455
- van den Bosch MA, Daniel BL, Mariano MN, Nowels KN, Birdwell RL, FongKJ, et al. Magnetic resonance imaging characteristics of fibrocystic change of the breast. Invest Radiol 2005; 40: 436-41.
- Kiyak G, Asik E, Yazgan A. Magnetic resonance imaging characteristics of fibrocystic change of the breast. Bratisl Lek Listy 2011; 112: 506-9
- Jansen SA, Fan X, Karczmar GS, Abe H, Schmidt RA, Giger M, et al.DCE MRI of breast lesions: Is kinetic analysis equally effective for both:mass and non mass-like enhancement? Med Phys 2008; 35: 3102-9. doi:10.1118/1.2936220
- Agrawal G, Su MY, Nalcioglu O, Feig SA, Chen JH. Significance of breast lesion descriptors in the ACR BIRADS MRI lexicon. Cancer 2009; 115: 1363-80. doi:10.1002/cncr.24156
- Tozaki M, Fukuda K. High-spatial-resolution MRI of non-masslike breast lesions: interpretation model based on BI-RADS MRI descriptors. AJR Am J Roentgenol 2006; 187: 330-7. 10.2214/ajr.187.3.w330
- Rahbar H, Partridge SC. Multiparametric MR imaging of breast cancer. Magn Reson Imaging Clin N Am 2016; 24: 223-38. 10.1016/j.mric.2015.08.012
- Bartella L, Liberman L, Morris EA, Dershaw DD. Nonpalpable mammographically occult invasive breast cancers detected by MRI. AJR Am J Roentgenol 2006; 186: 865-70. 10.2214/AJR.04.1777
- Goto M, Ito H, Akazawa K, Kubota T, Kizu O, Yamada K, et al. Diagnosis of breast tumors by contrast-enhanced MR imaging: comparison between the diagnostic performance of dyamic enhancement patterns and morphologic features. J Magn Reson Imaging 2007; 25: 104-12. 10.1002/jmri.20812
- Newell D, Nie K, Chen JH, Hsu CC, Yu HJ, Nalcioglu O, et al. Selection of diagnostic features on breast MRI to differentiate between malignant and benign lesions using computer-aided diagnosis: differences in lesions presenting as mass and non-mass-like enhancement. Eur Radiol 2010; 20:771-81. 10.1007/s00330-009-1616-y
- Kaiser WA. Signs in MR-Mammography. Berlin Heidelberg: Springer-Verlag; 2008.
- Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast - risk assessment and management options. N Engl J Med 2015; 372: 78-9. 10.1056/NEJMsr1407164
- Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer JClin 2007; 57: 75-89.
- Ochi M, Kuroiwa T, Sunami S, Murakami J, Murakami J, Miyahara S, Nagaie T, et al. Diffusion-weighted imaging (b value = 1500 s/mm (2)) is useful to decrease false-positive breast cancer cases due to fibrocystic changes. Breast Cancer 2013; 20: 137-44. 10.1007/s12282-011-0319-9
- Nadrljanski MM, Gusic N, Milovanovic Z, Plesinac-Karapandzic V, Radulovic O, Milosevic ZC. Fibrocystic changes of the breast: lesion characterization using dynamic contrast-enhanced and diffusion-weighted MR images. ECR 2013, EPOS. Available at: http://dx.doi.org/10.1594/ecr2013/C-0868.